Reset Pharma is a neuro-biotechnology company dedicated to improving mental health through novel pathways.
Our Ambition
We exist to help people move beyond the psychological trauma of a life-threatening diagnosis.
Our focus lies where needs are most urgent: helping people overcome demoralization syndrome due to life-altering diseases, such as cancer.
Our Science
We are developing transformative, first-in-class, psilocybin-inspired therapies that have the potential to reset neural networks in the brain and reconnect people to meaning in their lives.1,2
Our Partners
We are breaking new scientific ground in collaboration with leading research institutions, including acquiring a worldwide license from NYU based on the seminal work of Stephen Ross, MD—a leading researcher in the field of psychedelic medicine and psycho-oncology.
To bring our treatment to market, Reset Pharma has established a highly experienced neuro-biotechnology team.
References
1. Grandjean J, Buehlmann D, Buerge M, et al. Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice. Neuroimage. 2020;225(2021):117456. doi:10.1016/j.neuroimage.2020.117456
2. Carhart-Harris RL, Roseman L, Bolstridge M, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2021;7(1):13187. doi:10.1038/s41598-017-13282-7